Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Strong Results But Merck & Co’s Keytruda Also Competing
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
